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Abstract 
Based on the capacity to increase IP 3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists can be subdivided into two classes: ATP, 
ADP, UTP, 2deoxyATP, NAD and GTP significantly increased IP 3 levels whereas ADPflS, 2MeSATP, NADP, a,/3MeATP, 
fl,yMeATP and ATPc~S had only a minor, non-significant effect. Irrespective of their potency to increase IP 3, all agonists were full 
glycogenolytic agonists and they all increased cytosolic calcium. With ATP and NAD, IP 3 increasing agonists, and 2MeSATP and 
ADP/3S, non-IP 3 increasing agonists, we found that the initial calcium response appeared to be an 'all or none' phenomenon, small 
amounts of the agonists being either ineffective or equally effective as high amounts. The minimal amount of an agonist needed to initiate 
a calcium increase and to promote glycogenolysis was very similar. In the absence of extracellular calcium, both groups of purinergic 
agonists (tested with ATP and 2MeSATP) were equally able to release calcium from intracellular stores. Cells with emptied intracellular 
calcium stores rapidly took up extracellular calcium upon treatment with ATP or 2MeSATP, the latter being the most potent. It seems 
therefore that all nucleotides tested increased cytosolic alcium and activated phosphorylase in a very similar way but some nucleotides 
had no effect on the levels of IP 3. 
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1. Introduction 
With rat hepatocytes it has been shown that extracellu- 
lar ATP, via a calcium-dependent mechanism activates 
glycogenolysis [1]. The rank order of potency of a series of 
ATP analogs (2-methylthio adenosine trisphosphate 
(2MeSATP)  > ATP = ADP > a , /3 -methy lene-ATP 
(a, /3MeATP) and the fact that ATP increases IP 3 and 
diacylglycerol levels suggested the presence of purinocep- 
tors from the Per subclass [2-4]. However, a more detailed 
analysis of the effects on hepatocytes produced by 
2MeSATP, the most potent glycogenolytic purinergic ago- 
nist [5], and by ADP/3S [6,7], a specific P2v agonist in 
turkey erythrocytes [8], revealed a more complex situation 
and consequently biased the classical nomenclature. In- 
deed, in clear contrast o ATP, 2MeSATP and ADP/3-S (a) 
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hardly increase the levels of IP 3 (measured as a mixture of 
all inositol-polyphosphates) and (b) their effect on glyco- 
gen phosphorylase is blocked by phorbol ester pretreat- 
ment of the hepatocytes. The enigmatic situation of the 
liver purinoceptor classification and mechanism is further 
illustrated by the different calcium increase patterns in 
single hepatocytes produced by ATP and ADP [9], be- 
tween the diadenosine-trisphosphate (AP3A) and diadeno- 
sine-tetraphosphate (Ap4A) [10] and by the fact that UTP 
also activates glycogen phosphorylase in an identical way 
as does ATP [11]. It seems therefore that liver possesses 
multiple purinoceptors and/or  also a nucleotide type of 
receptor [12]. Van Rhee et al. [7] also presented evidence 
for the presence of P2u-purinoceptor and/or  nucleotide 
receptors on liver parenchymal cells, mediating a calcium 
influx rather than an IP3-mediated mobilization of calcium. 
These data, recently reviewed [1], suggest hat the levels of 
IP 3 need not necessarily be increased in order to provoke a 
calcium-mediated glycogenolysis n hepatocytes. This pa- 
per further substantiates this idea for liver glycogenolysis 
initiated by ATP, ATP-analogs, GTP and UTP. 
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2. Materials and methods 
2.1. Materials 
We used male Wistar.-strain albino rats (200-250 g 
body wt.) that were fed ad libitum. IP 3 and cAMP assay 
kits, ATPaS (adenosine 5'-[ce-thio]triphosphate and 
[ 3 H]inositol-(1,4,5)-trisphcsphate wer from Amersham In- 
ternational, Amersham, Bucks., UK; ATP, ADP, ADP/3S 
(adenosine 5'-[/3-thio]diphosphate) w re from Boehringer, 
Manheim, Germany; 2-methylthio-ATP was from Re- 
search Biochemicals, Natick, MA, USA; NAD, UTP, 2de- 
oxy-ATP, pp[CH 2 ]pA (c~,/3-methyI-ATP) and p[CH 2 ]ppA 
(/3,y-methyl-ATP) were from Sigma Chemicals, St. Louis, 
MO, USA; NADP was from Serva, Heidelberg, Germany; 
GTP was from P-L Biochemicals, Milwaukee, WI, USA; 
glucagon was from Novo Laboratories Copenhagen, Den- 
mark. 
2.2. Methods 
Liver cells were isola~:ed and incubated in a Krebs- 
Henseleit bicarbonate buffer equilibrated with O2/CO 2 
(19:1, v /v)  as previously described [13]. Briefly, the liver 
was perfused at 37°C for about 10 rain with a Krebs- 
Henseleit bicarbonate buffer without calcium followed by 
a 25-30 rain perfusion with collagenase (30 mg/100 ml 
of perfusion buffer) and calcium (2.5 mM). The hepato- 
cytes were harvested and incubated at 37°C in a Krebs- 
Henseleit buffer containing 10 mM glucose in closed 
plastic vials saturated with 95% 0 2, 5% CO 2 (v/v). These 
cells were then treated with the different agonists and 
samples were taken after 7 s for the determination of 
inositol 1,4,5 trisphosphate [11] and after 20 s for glycogen 
phosphorylase [14]. Samples for IP 3 determination were 
mixed with trichloroacetic acid (TCA) (14% final concen- 
tration) and EDTA (5 mM final concentration). After 
extraction of the TCA and neutralisation of the samples 
(pH 7.4), IP 3 was determined with a competitive protein- 
binding technique based on a procedure described by Bredt 
et al. [15] with slight modifications. Cerebellum plasma 
membranes, containing the IP 3 binding protein, were puri- 
fied from rabbit brain as described [11]. The incubation 
medium contained about 50/~g of these membranes, 1 nM 
[3H]IP3 and 10 /zl cell extract in a final volume of 100 /zl. 
Bound and free ligand were separated after 10 min of 
incubation at 4°C by filtration through Whatman GF/A  
filters, which were washed three times with 7 ml 50 mM 
Tris-HC1 (pH 8.4) and 1 rnM EDTA. Radioactivity of the 
digested filters was dete, rmined by liquid scintillation 
counting. Sampling of hepatocytes and assaying of glyco- 
gen phosphorylase activity was as described by Vanden- 
heede et al. [ 13]. 
Intracellular Ca 2+ was measured using Fura-2 fluores- 
cence spectroscopy. Cells were loaded with the ace- 
toxymethylester of Fura-2 (Fura-2-AM) by incubation of 
hepatocytes (0.5 to 1 × 10 6 cells ml - I )  in a solution 
containing 118 mM NaC1, 4.7 mM KCI, 1.2 mM KH2PO 4, 
1.2 mM MgSO 4, 25 mM NaHCO 3, 10 mM glucose, 4.5 
mM glutamate, 5 mM pyruvate, 20 mM Hepes and 2 mM 
CaCI 2 at a pH of 7.4 and supplemented with 1% BSA, 
0.05% pluronic acid, 10 /xM Fura-2-AM and 0.5 % 
dimethylsulfoxide at 30°C for about 20-30 min. The cells 
were then extensively washed and transferred into a cu- 
vette with a thin glass bottom, lightly coated with polyly- 
sine. The cuvette is mounted on an inverted Nikon Diaphot 
microscope, equipped with a dual excitation microspec- 
trofluorimetric system (Newcastle Photometric System). 
Fura-2 was alternatively excited at 340 and 380 nm and 
emission fluorescence was collected at 510 nm. Measure- 
ments were performed at room temperature. [Ca 2+ ] was 
calculated from the ratio of fluorescence according to the 
equation [Ca 2+ ] = K d × B × (R  - Rmin) / (Rma x - -  R) [16], 
with K d = 224 nM, B is the ratio of the fluorescence 
signals obtained by illuminating the cells at 380 nM taken 
at 0 (EGTA) or saturating Ca2+-concentrations (ionomy- 
cin, 4-bromo A23187). R represents he ratio at any time, 
whereas Rma x and Rmi n are the ratios obtained at saturat- 
ing respectively zero calcium. The autofluorescence n ver 
exceeded 10% of the fluorescence of a Fura-loaded cell 
and was subtracted from the total fluorescence. 
3. Results 
3.1. Quantification of  the IP 3 increase 
From our previous studies we knew that ADPflS [6] 
and 2MeSATP [5], in contrast to ATP and UTP [11], had 
only a minor effect on the levels of inositol polyphos- 
phates tIP 3, IP 4, IP 5, IP6..). We first wanted to quantify the 
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Fig. 1. Time-dependent increase in IP 3 in hepatocytes after ATP and 
2MeSATP. Hepatocytes were preincubated with 10 mM glucose for 
20-30 min and then challenged with 50 (O) or 10 /a.M of ATP (O) or 
with 10 /xM of 2MeSATP (r-q). At the indicated times, samples were 
taken for the assay of IP 3. Data shown were taken from one representa- 
tive experiment (see also Ref. [11] for kinetics). 
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Table 1 
Effect of various nucleotides on the level of inositol-l,4,5-trisphosphate 
(IP 3) in hepatocytes 
Nucleotide p,M IP 3 (% of control) ~°"~>5o /zM 
mean +S.E.M. (n) P 
ATP 20 150+16(5)<0.05 0.5* 
50 590+ 85 (21) < 0.05 
2000 520 + 22 (3) < 0.05 
ADP 2000 493 __+ 50 (3) < 0.05 0.3 * 
ADPflS 400 91 + 15 (7)N.S. 1.0. * 
2000 148_+10(3)<0.05 
2MeSATP 40 122 4- 14 (6) N.S. 0.032 * * * 
2000 235 4- 75 (5) N.S. 
NADP 2000 106 -+ 4 (3) N.S. 400 * 
10000 154-+ 29 (3) N.S. 
a,/3 MeATP 500 99+2 (3) N.S. 50* 
2000 162 _+ 22 (4) N.S. 
fl,',/MeATP 200 105 _+ 10 (3) N.S. 3.2 * 
1000 162_+ 24 (3) N.S. 
NAD 2000 157 _ 4 (3) < 0.05 25 
UTP 10 218+14(3)<0.05 1 .***  
500 554___44(11)<0.05 
2deoxyATP 2000 435 _+ 48 (3) < 0.05 1 
GTP 2000 399-+61 (3) < 0.05 12.5, 
ATPaS 20 148_ 13 (3) N.S. 0.25* 
100 155_+ 24 (6) N.S. 
IP 3 levels were determined 7 s (see Section 2) after the addition of the 
different agonists at the indicated concentration. Values listed are means 
+ S.E.M. for (n) independent experiments, each done in triplicate. They 
are expressed as % of control, taken as 100% (mean basal value 
(+S.E.M.) of IP 3 was 20.8+3.8 (n = 28) pmol/mg of protein). P-val- 
ues were calculated from the Student -test analysis of the data. P > 0.05 
is indicated as not significant (N.S.). ECs0-values, indicating the concen- 
tration at which the agonist half maximally activates phosphorylase, were 
newly determined or taken from *Ref. [18], * *Ref. [6], * * *Ref. [5], 
• * * *Ref. [11]. 
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effect specifically on IP 3 (inositol 1,4,5-trisphosphate) lev- 
els after these and other glycogenolytic nucleotides. Fig. i 
shows the time-dependent i crease of IP 3 in hepatocytes 
treated with ATP and 2MeSATP. Maximal increases are 
observed within 10 s (see also Ref. [11]). Hepatocytes 
were therefore treated for 7 s with the different agonists 
listed in Table 1 and at concentrations much higher than 
those needed to half-maximally activate glycogen 
phosphorylase (this can be judged from the included 
ECs0-values). From this table it appears that high concen- 
trations of ATP, ADP, UTP, 2deoxyATP, NAD and GTP 
significantly increased IP 3 levels, whereas the other ago- 
nists did not. Like ATP, none of the tested agonists 
increase cAMP but, except for 2MeSATP [5] they all 
antagonized the glucagon effect on the levels of cAMP 
(not shown). 
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Fig. 2. Dose-dependent i crease in IP 3 and activation of phosphorylase in 
hepatocytes after 2MeSATP (compared with ATP). Hepatocytes were 
preincubated with 10 mM glucose for 20-30 min and then challenged 
with the indicated concentrations of 2MeSATP or ATP. IP 3 levels were 
determined 7 s after either 2MeSATP (O) or ATP (El), phosphorylase 
was assayed 20 s after 2MeSATP (0 )  or ATP (11). Data shown are the 
means of two independent experiments. (See also Ref. [5] for the dose-de- 
pendent activation of phosphorylase after 2MeSATP, ECs0-value in Table 
1, and Ref. [11] for the effects after ATP.) 
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Fig. 3. Increase of intracellular calcium after different concentrations of 
ATP and 2MeSATP in single hepatocytes loaded with Fura 2. Single 
hepatocytes, loaded with Fura 2, were superfused with the indicated 
concentrations of ATP (upper part, except for the last calcium increase 
pattern which is due to the indicated concentration of 2MeSATP) or of 
2MeSATP (lower part) for a time period indicated by the horizontal bar. 
Calcium concentration was calculated according to [6]. The graph shows 
one experiment (an interrupt of the curve indicates that a new cell is 
challenged) representative of several similar experiments, obtained with 
different cell preparations. 
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The difference between the two classes is further illus- 
trated in Fig. 2, showing the dose-dependent activation of 
glycogen phosphorylase after 2MeSATP, clearly not corre- 
lated with changes in IP3-1evels. 2MeSATP is the most 
potent glycogenolytic pur~nergic agonist in liver. For com- 
parison, Fig. 2 also show~,; the effects after ATP. From the 
IP 3 data obtained after 2MeSATP it seems that very high 
concentrations of 2MeSATP will eventually also augment 
IP3. 
3.2. Calcium increases, dose dependency 
Based on their potency to increase IP 3, it is obvious that 
there are two groups of purinergic agonists. We therefore 
checked whether both types of nucleotides increased cy- 
tosolic calcium in single hepatocytes loaded with fura-2 
and to what extent. All agonists, used at the highest 
concentration (listed in Table 1), increased cytosolic cal- 
cium to about the same level and with a very similar 
pattern: they all produced a rapid increase followed by a 
slow decay (see Fig. 3 for an example). For a few analogs 
(ATP, 2MeSATP, ADPfl S and NAD) we applied increas- 
ing concentrations and checked their effect on the cytoso- 
lic calcium levels. Calcium increases occurred in an 'all or 
none' way, i.e., low doses had either no effect or produced 
a full initial response. The concentration which in some 
cells did induce a calcium increase while it failed in others 
was considered as the 'onset' concentration for the calcium 
changes. Fig. 3 illustrates the result of such experiments 
carried out with ATP ('onset' concentration between 0.1 
and 0.3 /xM), and 2MeSATP ('onset' concentration be- 
tween 0.01 and 0.03 /zM). Similar results (not shown) 
were obtained with ADP/3S ('onset' concentration around 
1 /xM) and NAD ('onset' between 10 and 30 /zM). 
3.3. Characterization of  the cytosolic calcium increases 
To further characterize the cytosolic calcium increases 
induced by the two groups of purinergic agonists, we 
studied the effects of ATP and 2MeSATP on cells in the 
absence of extracellular calcium and also on cells of which 
the intracellular calcium stores had been emptied. It is 
obvious from Fig. 4 (see also Fig. 3) that in the presence 
of extracellular calcium there was little or no difference 
between ATP and 2MeSATP: both agonists rapidly in- 
creased cytosolic calcium. Superfusion of the cells with a 
calcium-free medium (supplemented with 0.5 mM EGTA 
so as to immediately remove all extracellular calcium) 
initially did not prevent he cytosolic calcium increases 
after ATP or 2MeSATP. Both ATP and 2MeSATP seemed 
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Fig. 4. Effect of extra- and intraceUular calcium on hepatocyte cytosolic calcium after ATP and 2MeSATP. Single hepatocytes were loaded with Fura 2 
and superfused with a buffer solution containing 1.3 mM calcium (hatched bars) or without calcium, supplemented with 1 mM EGTA (solid bars). From 
time to time 5 ~M ATP (a and b) or 0.5 /.LM 2MeSATP (c and d) was added to the superfusing medium for a time period indicated by the open bars. Two 
representative examples for each agonist are shown. (Dotted line: see Table 2.) 
320 S. Keppens, H.D. Wulf / Biochimica et Biophysica Acta 1269 (1995)316-322 
Table 2 
Relative rate of calcium influx in hepatocytes after 2MeSATP and ATP 
Mean relative velocity of 
calcium influx + S.E.M. (n) 
ATP 100 
2MeSATP 299 ~ + 57 (15) 
Hepatocytes were superfused without calcium (buffer supplemented with 
0.5 mM EGTA). Their intracellular calcium pools were emptied by 
pretreating these cells with 5 /xM ATP (or 0.5 /xM 2MeSATP). After 
washing away the agonists, the cells were again superfused with ATP (or 
2MeSATP) but this time in the presence of calcium (2 mM). The rate of 
calcium influx observed in this condition was estimated as indicated by 
the dotted line in Fig. 4. Due to differences between different cell 
preparations we expressed the velocity of the calcium influx relative to 
the one observed after ATP (taken as 100) in each preparation. We 
analyzed 5 different cell preparations and in each preparation three 
experiments were conducted with ATP and three with 2MeSATP. 
P = 0.0061 (Student -test of paired data). 
(IP~, IP 5, IP6). Our results corroborate the data of Okajima 
et al. [17], who also reported the existence of two groups 
of ATP analogs based on the IP 3 increase. However, at 
variance with their findings, we did not observe a different 
glycogenolytic potency for the two groups of analogs. We 
determined the glycogenolytic potency 20 s after the addi- 
tion of the different agonists [14,18] (see also Ref. [19]), 
whereas Okajima et al. [17] assayed it only after 5 min. 
The different glycogenolytic potencies reported by Oka- 
jima et al. [17] as compared with our work might be due to 
the different susceptibility of the agonists to degradation. 
The assay technique for IP 3 used by Okajima et al. [17] is 
probably less dependent on the time of sampling since a 
mixture of inositolpolyphosphates, metabolites of IP 3, is 
measured. 
4.2, IP 3 leuels and calcium: are they interrelated? 
to be equally able to effectively and fully release calcium 
from internal stores. Cells had to be superfused (or prein- 
cubated) for at least 15 min without calcium in order to 
prevent ATP or 2MeSATP to elicit a cytosolic calcium 
increase. The cells became first insensitive to 2MeSATP 
and later also to ATP (not shown). The time needed to 
empty the calcium stores was considerably shortened by 
treating the cells with EGTA in the presence of the ago- 
nist. A second (or sometimes a third) addition of ATP or 
2MeSATP then became ineffective within a few minutes 
(see Fig. 3). Reapplication of calcium to these cells with 
'empty' stores, resulted in a slight increase in cytosolic 
calcium (see part of Fig. 4b,c). In the presence of calcium 
plus ATP, however, there was a manifest influx (reuptake) 
of calcium. Superfusing with calcium plus 2MeSATP in- 
duced a more rapid increase in cytosolic calcium. The 
difference in velocity of the initial calcium uptake after 
ATP and 2MeSATP, was estimated from the slope of the 
linear part of the calcium increase curve (represented by 
the dotted line in Fig. 4). Table 2 illustrates that 2MeSATP 
was about 3 times more able to induce the initial calcium 
reuptake. 
4. Discussion 
4.1. Two groups of purinergic agonists 
It is obvious from Table I that there are two groups of 
ATP analogs. They are both able to activate glycogen 
phosphorylase, but only one group increases the IP 3 levels: 
ATP, GTP, UTP, ADP, NAD and 2deoxyATP. The IP 3- 
levels reported are those of inositol- 1,4,5-trisphosphate, the
biologically active form and cannot as such be compared 
with older measurements of IP3-1evels where we and others 
rather measured a mixture of inositolpolyphosphates (in-
ositol-l,4,5-trisphosphate, inositol-l,3,5-trisphosphate) to- 
gether with other polyphosphorylated inositol derivatives 
Since it has been demonstrated that liver glycogen 
phosphorylase activtion is correlated with an increase in 
cytosolic calcium [19], the above-mentioned data suggest 
that either there are two different mechanisms to activate 
phosphorylase, one via IP3-released calcium, the other in 
an IP3-independent way, or alternatively all agonists acti- 
vate glycogen phosphorylase by a similar mechanism in 
which an increase of the level of IP 3 plays no mayor role. 
The latter hypothesis eems to be compatible with the 
observations that: (a) all agonists, irrespective of their 
ability to increase IP 3, increase cytosolic alcium in a very 
similar way: a rapid increase followed by a slow decay 
(see Fig. 2, examples for ATP and 2MeSATP, see also 
Ref. [6]) and (b) the minimal concentration of ATP, NAD, 
ADP/3S or of 2MeSATP needed to induce a calcium 
increase (assayed in single cells) fits with the onset of 
phosphorylase activation (measured in a cell suspension) 
and not with the onset of a IP 3 increase. Indeed one needs 
about 50 times less ATP to activate glycogen phospho- 
rylase than to increase IP 3 (see Fig. 2 and also Ref. [11]), 
and with 2MeSATP there is even a 1000-fold difference 
between the doses needed to activate phosphorylase or 
initiate calcium increases and those needed to observe a 
moderate increase in IP 3. It should be mentioned that we 
cannot as such compare results obtained with single cells 
(Ca 2÷) to those obtained in a cell suspension (phospho- 
rylase and IP3). Moreover, since we studied the calcium 
increase only for a short time (seconds) after the different 
agonists, we cannot really estimate the overall or 'effec- 
tive' calcium increase in a cell. The effective calcium 
concentration is not only determined by the degree of 
calcium increase (the same with low and high concentra- 
tions of ATP) but also by the frequency with which these 
calcium increases are observed (see Ref. [20]). Our data 
thus show that even a slight activation of phosphorylase is 
accompanied with 'a' calcium increase. 
From our earlier studies of the ATP receptor in rat liver 
cells and plasma membranes with ATPa[35S] as radioli- 
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gand, we knew that there', is only one binding component 
mediating the activation of glycogen phosphorylase [18]. 
We now report hat ATPe~ S does not increase the levels of 
IP 3 (Table 1), further supporting the hypothesis that IP 3 
must not necessarily be increased to induce glycogeno- 
lysis. 
4.3. Calcium increase pai:terns 
From the data obtained with hepatocytes incubated in 
the absence of extracellular calcium it is clear that not only 
ATP, but also 2MeSATP is able to significantly and 
rapidly induce the relea,;e of calcium from intracellular 
stores, and this without increasing the levels of IP 3. This 
calcium increase is transient due to the limited capacity of 
the stores. Readdition of calcium to these 'empty' cells 
results in only a slight increase in cytosolic calcium. 
Addition of ATP together with calcium, however, clearly 
increases the cytosolic calcium, suggesting a pronounced 
reuptake of calcium. In this respect, 2MeSATP is about 3 
times more effective compared to ATP. These data suggest 
that in these (drastic) conditions calcium influx could be 
more important for 2MeSATP than for ATP. We have to 
be very careful, however, in drawing conclusions from 
data obtained with cells incubated in the absence of extra- 
cellular calcium. It has indeed been shown that ce-adren- 
ergic agonists via interaction with the c~-adrenergic recep- 
tor can increase cAMP levels when cells are incubated in 
the absence of calcium [21]. 
These data cultivate the growing belief that, in some 
specific cases, an increase in IP 3 might not be the sole or 
major factor mediating the increase of cytosolic alcium. It 
has indeed recently been reported that for norepinephrine 
and even for vasopressin, the paradigm of the link between 
IP 3, calcium and liver glycogenolysis is not entirely depen- 
dent on the triggering of PIP2-phospholipase C activity and 
inositol trisphosphate formation [22]. Also in human 
platelets it has been reported that some effects of ADP can 
be disconnected from the IP 3 pathway [23,24]. And more 
recently Vigne et al. [25], using brain capillary endothelial 
cells, demonstrated that the calcium increases observed 
after 2MeSATP were not due to changes in IP 3. The latter 
finding completely corroborates our observations with 
2MeSATP in liver cells. 
These data do not necessarily exclude a role for IP 3 in 
mediating the cytosolic calcium increases, they merely 
suggest hat IP~ must not be increased to provoke calcium 
release. Resting levels of IP 3 could possibly mediate the 
release of calcium provided that the sensitivity of the 
'IP3-calcium'-release system is amplified. Such a sensitiza- 
tion can be set up by increased levels of cAMP [26,27], by 
sulfhydryl reagents [27,28] or by some cytosolic compo- 
nents as described for basophilic leukemia cells [29]. In 
liver, a sensitization through cAMP can be excluded since 
none of the tested agonists increases the levels of cAMP 
nor is it known that ATP would change the oxido reduc- 
tion status of the cell or would generate a cytosolic factor 
which sensitizes the IP3-calcium system. Alternatively it 
might be that IP 3 is indeed increased but is rapidly con- 
verted to IP 4 by stimulation of the inositol 1,4,5-tri- 
sphosphate-kinase. An increase in IP 4 (and not IP 3) has 
indeed been reported in DDT1MF-2 smooth muscle cells 
mediated via P2-purinoceptors [30]. Also, in rat brain 
cortical slices Myles and Fain reported an increase in IP 4 
specifically after carbachol and not after, for instance, 
norepinephrine [31]. The role of IP 4 is then to promote 
calcium increases either on its own or in synergy with the 
basal levels of IP 3 (see [32] for Refs.). 
Apart from increasing IP 3, ATP also affects the levels 
of DAG (diacylglycerol) and PA (phosphatidic acid). The 
origin of these metabolites have been shown to predomi- 
nantly stem from hydrolysis of phosphatidilcholine (PC) 
either by a PC specific phospholipase C or by phospho- 
lipase D [22,33,34]. DAG is a known stimulator of PK-C, 
whereas PA is described as a multifunctional metabolite 
[35]. From these papers it is obvious that glycogenolysis i  
rather correlated with PC hydrolysis than with breakdown 
of phosphtidylinositol-bisphosphate (PIP2). The exact 
mechanism through which PC hydrolysis will eventually 
increase cytosolic alcium is, however, not elaborated. The 
same remark holds for the possible ffect in liver of cyclic 
ADP-ribose, a known mediator of calcium increases in 
many cells. So far, an effect of cyclic ADP-ribose in liver 
has still to be demonstrated, espite the presence of high 
affinity binding sites for ryanodine [36]. Cyclic ADP-ribose 
is reported to induce the release of calcium from stores 
responsive to ryanodine and not to IP 3 (see, for instance, 
Ref. [37]). 
From these data it can be concluded that GTP, UTP, 
ATP and its analogues all increase cytosolic calcium irre- 
spective of their capacity to increase the levels of inositol 
1,4,5-trisphosphate in liver cells. 
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